Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment

E. Solcia, R. Fiocca, N. Havub, A. Dalväg, R. Carisson

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Both argyrophil endocrine cells and gastritis were investigated in 2.120 biopsies of gastric corpus mucosa from 443 out of 44S patients receiving long-term (for periods ranging from several months to 4 years) omeprazole treatment. None of the patients showed neoplasia or dysplasia, either endocrine or non-endocrine. In 123 out of the 443 patients (27.8%). endocrine hyperplasia of diffuse (9.3%). linear (4.1%) or micronodttlar (14.4%) type was detected either before or at some time during treatment. Chronic atrophic gastritis was found in 45 (10.2%) patients. 60% of whom also showed micronodttlar hyperplasia. In patients with chronic atrophic gastritis, micronodular hyperplasia occurred in 49% of % biopsies, compared with n% of 1.083 biopsies from patients with non-atrophic chronic gastritis and 2% of 941 biopsies from patients with no evidence of gastritis. In 202 patients treated with omeprazole for at least 330 days, the incidence of micronodular hyperplasia increased from 2.5% at the first biopsy to 10.4% at the final biopsy, while the incidence of chronic atrophic gastritis increased from 1.0% to 13.0%. The present and parallel studies suggest that progression of gastritis is inherent in the natural history of acid-related diseases, while endocrine cell changes are mostly secondary to gastritis-related gland atrophy and have no lumorigenic potential.

Original languageEnglish
Pages (from-to)82-92
Number of pages11
JournalDigestion
Volume51
DOIs
Publication statusPublished - 1992

Fingerprint

Endocrine Cells
Omeprazole
Gastritis
Stomach
Biopsy
Atrophic Gastritis
Hyperplasia
Therapeutics
Incidence
Gastric Mucosa
Natural History
Atrophy
Acids

Keywords

  • Ciastritis
  • Endocrine hyperplasia
  • Long-term treatment
  • Omeprazole
  • Safety

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. / Solcia, E.; Fiocca, R.; Havub, N.; Dalväg, A.; Carisson, R.

In: Digestion, Vol. 51, 1992, p. 82-92.

Research output: Contribution to journalArticle

@article{b661bbf9948b488e99815ad82934196d,
title = "Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment",
abstract = "Both argyrophil endocrine cells and gastritis were investigated in 2.120 biopsies of gastric corpus mucosa from 443 out of 44S patients receiving long-term (for periods ranging from several months to 4 years) omeprazole treatment. None of the patients showed neoplasia or dysplasia, either endocrine or non-endocrine. In 123 out of the 443 patients (27.8{\%}). endocrine hyperplasia of diffuse (9.3{\%}). linear (4.1{\%}) or micronodttlar (14.4{\%}) type was detected either before or at some time during treatment. Chronic atrophic gastritis was found in 45 (10.2{\%}) patients. 60{\%} of whom also showed micronodttlar hyperplasia. In patients with chronic atrophic gastritis, micronodular hyperplasia occurred in 49{\%} of {\%} biopsies, compared with n{\%} of 1.083 biopsies from patients with non-atrophic chronic gastritis and 2{\%} of 941 biopsies from patients with no evidence of gastritis. In 202 patients treated with omeprazole for at least 330 days, the incidence of micronodular hyperplasia increased from 2.5{\%} at the first biopsy to 10.4{\%} at the final biopsy, while the incidence of chronic atrophic gastritis increased from 1.0{\%} to 13.0{\%}. The present and parallel studies suggest that progression of gastritis is inherent in the natural history of acid-related diseases, while endocrine cell changes are mostly secondary to gastritis-related gland atrophy and have no lumorigenic potential.",
keywords = "Ciastritis, Endocrine hyperplasia, Long-term treatment, Omeprazole, Safety",
author = "E. Solcia and R. Fiocca and N. Havub and A. Dalv{\"a}g and R. Carisson",
year = "1992",
doi = "10.1159/000200921",
language = "English",
volume = "51",
pages = "82--92",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment

AU - Solcia, E.

AU - Fiocca, R.

AU - Havub, N.

AU - Dalväg, A.

AU - Carisson, R.

PY - 1992

Y1 - 1992

N2 - Both argyrophil endocrine cells and gastritis were investigated in 2.120 biopsies of gastric corpus mucosa from 443 out of 44S patients receiving long-term (for periods ranging from several months to 4 years) omeprazole treatment. None of the patients showed neoplasia or dysplasia, either endocrine or non-endocrine. In 123 out of the 443 patients (27.8%). endocrine hyperplasia of diffuse (9.3%). linear (4.1%) or micronodttlar (14.4%) type was detected either before or at some time during treatment. Chronic atrophic gastritis was found in 45 (10.2%) patients. 60% of whom also showed micronodttlar hyperplasia. In patients with chronic atrophic gastritis, micronodular hyperplasia occurred in 49% of % biopsies, compared with n% of 1.083 biopsies from patients with non-atrophic chronic gastritis and 2% of 941 biopsies from patients with no evidence of gastritis. In 202 patients treated with omeprazole for at least 330 days, the incidence of micronodular hyperplasia increased from 2.5% at the first biopsy to 10.4% at the final biopsy, while the incidence of chronic atrophic gastritis increased from 1.0% to 13.0%. The present and parallel studies suggest that progression of gastritis is inherent in the natural history of acid-related diseases, while endocrine cell changes are mostly secondary to gastritis-related gland atrophy and have no lumorigenic potential.

AB - Both argyrophil endocrine cells and gastritis were investigated in 2.120 biopsies of gastric corpus mucosa from 443 out of 44S patients receiving long-term (for periods ranging from several months to 4 years) omeprazole treatment. None of the patients showed neoplasia or dysplasia, either endocrine or non-endocrine. In 123 out of the 443 patients (27.8%). endocrine hyperplasia of diffuse (9.3%). linear (4.1%) or micronodttlar (14.4%) type was detected either before or at some time during treatment. Chronic atrophic gastritis was found in 45 (10.2%) patients. 60% of whom also showed micronodttlar hyperplasia. In patients with chronic atrophic gastritis, micronodular hyperplasia occurred in 49% of % biopsies, compared with n% of 1.083 biopsies from patients with non-atrophic chronic gastritis and 2% of 941 biopsies from patients with no evidence of gastritis. In 202 patients treated with omeprazole for at least 330 days, the incidence of micronodular hyperplasia increased from 2.5% at the first biopsy to 10.4% at the final biopsy, while the incidence of chronic atrophic gastritis increased from 1.0% to 13.0%. The present and parallel studies suggest that progression of gastritis is inherent in the natural history of acid-related diseases, while endocrine cell changes are mostly secondary to gastritis-related gland atrophy and have no lumorigenic potential.

KW - Ciastritis

KW - Endocrine hyperplasia

KW - Long-term treatment

KW - Omeprazole

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0026800744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026800744&partnerID=8YFLogxK

U2 - 10.1159/000200921

DO - 10.1159/000200921

M3 - Article

C2 - 1397749

AN - SCOPUS:0026800744

VL - 51

SP - 82

EP - 92

JO - Digestion

JF - Digestion

SN - 0012-2823

ER -